VERA Files
With the 2022 elections drawing near and the Duterte administration’s approval rating in fighting corruption dropping by 12 points in the latest survey, Malacañang appears to be slowly distancing itself from the Senate probe into Pharmally Pharmaceutical Corp.’s multibillion-peso contracts with the government.
She made no such allegation against the senator.
Ang ulat ng Commission on Audit (COA) tungkol sa P67.32 bilyong “deficiencies” sa pandemic response funds ng Department of Health (DOH) ay nagbunsod ng imbestigasyon ng kongreso sa paglilipat ng P42 bilyon sa Procurement Service sa Department of Budget and Management (PS-DBM). Ito naman ay humantong sa pagkakadiskubre ng P8.68 bilyon na mga kontrata ng supply sa Pharmally Pharmaceutical Corp.
The Commission on Audit (COA) report about the P67.32 billion “deficiencies” in the pandemic response funds of the Department of Health (DOH) triggered a congressional investigation on the transfer of P42 billion of the amount to the Procurement Service in the Department of Budget and Management (PS-DBM). This, in turn, led to the discovery of P8.68 billion in supply contracts with Pharmally Pharmaceutical Corp.
The problem with sourcing information from Davao city is that it always leads to a request for anonymity.